×
Hero Background

US Onychomycosis Companies

ID: MRFR/Pharma/1895-CR
30 Pages
Rahul Gotadki
April 2017

Onychomycosis, commonly known as nail fungus, is a fungal infection of the toenails or fingernails. The U.S. market for onychomycosis treatment involves pharmaceutical and healthcare companies that develop and market medications, topical solutions, and other therapeutic interventions.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Onychomycosis Market Research Report- Forecast To 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the US Onychomycosis Market

US Onychomycosis Key Companies

 

Latest US Onychomycosis Companies Update


Kerydin (Tavaborole) Patent Expiry: The key patent for Kerydin, a topical antifungal treatment for onychomycosis, expired in September 2023. This could lead to increased competition and potentially lower prices for patients.


Moberg Pharma Phase 3 Trial: Moberg Pharma, a Danish pharmaceutical company, is conducting a Phase 3 trial for MOB-003, a novel oral therapy for onychomycosis. Positive results could significantly impact the market landscape.


Blueberry Therapeutics Phase 2b Trial: Blueberry Therapeutics is pursuing a Phase 2b trial for its BLU-634 topical gel for onychomycosis. BLU-634 targets a different fungal pathway than existing treatments, offering potential for broader efficacy.


Almirall and Kaken Pharmaceutical Partnership: Almirall, a Spanish pharmaceutical company, entered a partnership with Kaken Pharmaceutical to commercialize Kaken's Luliconazole 5% solution (Luconac R) in the US market. Luconac R is a topical nail lacquer with a unique formulation compared to existing options.


Bausch Health Acquires Valeant Pharmaceuticals: Bausch Health's acquisition of Valeant Pharmaceuticals in May 2023 consolidated its hold on the US onychomycosis market. Valeant previously marketed Jublia (efinaconazole), a topical antifungal treatment.


List of US Onychomycosis Key Companies in the Market




  • Johnson & Johnson




  • Novartis AG




  • Valeant Pharmaceuticals




  • Pfizer Inc.




  • Anacor Pharmaceuticals




  • Galderma S.A.




  • Moberg Pharma AB




  • Bayer AG




  • Dr. Reddy’s Laboratories Ltd.




  • Cipla Ltd.




  • Medimetriks Pharmaceuticals Inc